Colonoscopies are no fun. These at-home colon cancer screenings offer a shortcut.

Getty Images; Alyssa Powell/BIColon cancer is the second-deadliest cancer in the US, partly due to low screening rates.New and emerging screening tools, like blood and breath tests, may offer alternatives to in-office screenings.This article is part of "Transforming Treatments," a series on medical innovations that save time, money, or discomfort.Colon cancer is the second-deadliest cancer in America. It's not deadly because it's particularly hard to treat or because oncologists are bad at spotting it. In large part, it's because people aren't getting their colon checked out often enough.Only about 1 in 5 adults who are between the ages of 45 and 49 is up to date on their colon cancer screening (older adults fare better, with around 7 in 10 completing it)."This is a highly preventable disease and we have to change the status quo so that people don't die," Dr. Paul Limburg, a gastroenterologist and chief medical officer at Exact Sciences, the company that makes one of the most popular do-it-yourself colon cancer screening tests, told Business Insider.A colonoscopy is still the most reliable tool, both for spotting colon cancer and for serving double duty as a colon-cleanup service. "I would still choose a colonoscopy for myself," Dr. Tim Cannon, a medical oncologist who directs the gastrointestinal cancer program at the Inova Schar Cancer Institute, told BI."It is considered the gold standard, you can detect precancerous polyps and take them out during the procedure, and you can do it less often" than DIY tests, Cannon said.However, a new suite of at-home tests is rapidly expanding.For those struggling to find an appointment, those who don't have great insurance, or those who are just squeamish about colonoscopies, there are some pretty painless precursors you can do to check things out.Some recently-approved tests check your blood or your stool for signs that something is awry. One highly anticipated test, which isn't out yet, may require nothing more than your breath.Here are four of the latest and greatest colonoscopy alternatives:The budget-friendly original: an at-home FIT testThe FIT test is one of the oldest and most inexpensive DIY tests to check for colon cancer.LetsGetCheckedThe fecal immunochemical test (aka FIT) has been around since the 1980s and is still a recommended screening tool today because it's cheap, relatively reliable, and requires no preparation."Fecal-immuno test is the most inexpensive," Dr. Asad Umar previously told BI. "People don't like to do it, because — maybe it's the 'yuck' factor — but this could be lifesaving."You typically perform the FIT in your bathroom after a bowel movement by collecting some stool out of the toilet bowl with a brush. After the kit is sent to the lab, it will be checked for hidden blood in the stool — an early colon cancer symptom.Since colon cancers don't constantly let out blood in your stool, the test isn't perfect. FIT is about 75% accurate at detecting colon cancer cases, and a smaller number of people (about 1 in 20) may get a false positive result when they don't have colon cancer.Method: StoolHow often: Once a yearCost: Prescriptions are free for everyone over 45 with insurance. Over-the-counter costs can range from $25-80.Pros: Easy to do at homeCons: May miss around 25% of casesThe pooper scooper: Cologuard stool testingStool tests like Cologuard are good at detecting cancer, but not preventing it.CologuardLike FIT, Cologuard is a stool test that you do in the bathroom, and then send into a lab for testing. Unlike FIT, Cologuard looks for both blood and cancerous DNA in your poop.Adding DNA to the mix makes Cologuard more successful: it picks up more than 9 in 10 colon cancer cases, and can flag some precancerous polyps. The downside is that Cologuard also sometimes flags poop samples that aren't cancerous, with roughly 1 in 10 patients receiving a false positive test reading.Anne Jones, a collegiate athlete career coach, was 46 when she first tried Cologuard. She knew that more women her age were being diagnosed with late-stage colon cancers, but she was hesitating about when to schedule her first colonoscopy. Did she really need to do this right now? A colonoscopy procedure requires several hours of prep work at home, emptying out your colon with heavy-duty laxatives. It's performed under anesthesia, so you need someone to pick you up from the hospital afterward."It was less the fear of the colonoscopy and more just the hassle," Jones said. When her doctor explained she could order a Cologuard test and do it on her own at home with zero prep, it seemed like a no-brainer."The doer in me is like 'great, let's do it.' I want to get this done. Cross it off the list."Crossing her colon cancer screening "off the list" ended up taking a few more steps, though, because Jones's Cologuard test came back positive. Within a few months, Jones went in for a colonoscopy, which found and removed multiple pre-cancerous polyps in her colon."It was not cancer, but there were three polyps that were pre-cancerous," Jones said. She said she's glad she was given the nudge to go under, though. "It just begs the question, if I had waited a year, might that have been different?"Cologuard, made by Exact Sciences, was first approved in 2014. In late 2024, the US Food and Drug Administration approved Cologuard Plus, which is more accurate than the regular Cologuard test and detects around 95% of colon cancers.Method: StoolHow often: Every three yearsCost: May be free with insurance. Out-of-pocket, around $650.Pros: Easy to do at homeCons: Price and possibility of false positivesThe blood draw: GuardantGuardant Health CEO, Helmy Eltoukhy.Guardant HealthGuardant Health has a new cancer screening test that skips the toilet and goes straight to your blood, analyzing your DNA for tell-tale clues that cancer could be lurking."What you're detecting is an abnormal molecule that is only created by a cancer," Guardant's Chief Medical Officer Dr. Craig Eagle told BI. "The more we learn what that looks like, the more we can actually find smaller and smaller amounts."Guardant's first colon cancer blood test, called Shield, was FDA-approved in July 2024. It's part of the company's suite of "liquid biopsies" that use blood to help doctors gain insights about cancer, whether for cancer diagnosis or in later stages to inform cancer treatment decisions.Guardant CEO Helmy Eltoukhy told BI he hopes that Shield can soon be harnessed to identify even more cancers, including some that are notoriously hard to detect, like pancreatic cancer. One federally funded study is recruiting 24,000 people across the US to test out Shield on multiple cancers."That's the beauty of this test: think of it as your iPhone, where initially it only had a few features. Over time, it has a thousand features," Eltoukhy told BI.Patricia James, now 77, was one of the first patients to try Shield in Guardant's pivotal clinical trial that ultimately led to its FDA approval last year. As a cancer survivor with a family history of colon cancer, she is a big believer in preventative care. But she doesn't really like colonoscopies, having had a rare but really bad experience during her first, when she woke up halfway through the procedure, and started "crashing around" on the operating table.After that, she said, she essentially swore off colonoscopies. She's getting older and has a greater risk of internal tearing and other rare complications from the procedure. So when her doctor mentioned there was a blood test available to screen for colon cancer, she said "sure."Shutterstock"There was no extra doctor's visit or anything," James told BI. She did it while she was in for a regular mammogram visit. She's now a huge advocate for the test, and even gave video testimony to Congress before it was FDA-approved."Look, I don't ever wanna mess around with my health, I've lost people to cancer and I battled it myself," she told the lawmakers. "I'm someone who wants all the time in the world to keep living. I have sung the praises of this test to friends and look forward to getting it again."Like the other screening tests mentioned here, Shield does have a risk of false-positive and false-negative results, but those inaccuracies decrease as cancer progresses. In other words, the further along cancer is, the better the test is at detecting it.Method: BloodHow often: Once every three yearsCost: Generally covered by insurance for those over 45, and by Medicare for older adults. The test costs around $1,500 out-of-pocket.Pros: No poop involvedCons: Requires a doctor's visit to collect blood. Also, roughly 1 of every 10 patients who don't have colon cancer may receive a false positive result, and 1 in 6 who do have cancer may receive a false negative.The breath test for colon cancerImagine that instead of collecting blood or poop to screen for colon cancer, all you have to do is breathe out for a few minutes.Several companies, in the UK, US, Canada, and Israel are working on innovative cancer screening tests that would pick up on volatile organic compounds in your breath. It's essentially like an emissions test for cancer.While none of these are available yet, the Israeli-based startup SpotitEarly is hoping to make its test available to consumers in the US as early as 2026, if all goes well with FDA regulators. A company-sponsored study published in November suggests the test is about 86% effective at picking up early-stage colon cancer cases (Stage 1 and 2).Method: BreathHow often: Not clear yetCost: Not available yetPros: Arguably the easiest test to perform, you just breathe for three minutesCons: It is not yet validated by the FDA, so it's unclear how well it can work. The goal is to detect cancer earlier than other tests. Read more from the Transforming Treatments series:In an era of quiet glow-ups, no-prep veneers are the new 'it' cosmetic procedureA do-it-yourself wand could help replace your next Pap smear (yes, really!) Read the original article on Business Insider

Comments

Business News

US importers bear brunt of Trump tariffs with higher consumer prices ‘in the pipeline’: Deutsche Bank

Newyork Post

Emanuel, Brigitte Macron sue Candace Owens for claiming French first lady was born a man who groomed her allegedly gay husband

about 4 hours ago

FCC Chair rips Stephen Colbert after his show’s abruptly canceled: He ‘clearly doesn’t have it anymore’

Newyork Post

Comments

Business News

US importers bear brunt of Trump tariffs with higher consumer prices ‘in the pipeline’: Deutsche Bank

‘CBS Mornings’ co-host Tony Dokoupil rips Jon Stewart, says ‘one-sided’ Stephen Colbert went too left

Skydance tells FCC it will scrap DEI, appoint media bias official at CBS News

Cleared City traders blame 'purge' as they hit out at rate-rigging prosecutions

Dramatic corkscrew spiral tree that creates a ‘show-stopping’ centrepiece is now 50% off

Ukraine is pumping millions of dollars into drones built to kill the Russian ones attacking its cities

Uber is finally releasing the feature I've been waiting for &mdash; a female driver option

Donald Trump is suing Rupert Murdoch. That doesn't mean the case will make it to court.

I was sick of spending my travel budget on weddings, so now I turn every invitation into a vacation

Grok has an AI chatbot for young kids. I used it to try to understand why.

I went to Maine and ranked 5 famous lobster rolls. My favorite was served up on the water's edge.

Sam Altman is worried some young people have an 'emotional over-reliance' on ChatGPT when making decisions

‘Top Chef’ Season 23 Will Film In The Carolinas—Here’s What Bravo Just Confirmed

Florida Judge Rejects Bid To Unseal Epstein Grand Jury Documents

The Alina Habba Saga Explained: How Trump May Get Her Back In Power—But Not As U.S. Attorney

FC Barcelona Makes Bombshell Preseason Announcement

Trump Administration Illegally Withheld Head Start Funds, Watchdog Finds

Emanuel, Brigitte Macron sue Candace Owens for claiming French first lady was born a man who groomed her allegedly gay husband

FCC Chair rips Stephen Colbert after his show’s abruptly canceled: He ‘clearly doesn’t have it anymore’

TPG revives Debenhams links with &#163;175m Boohoo debt deal

My most complimented gold earrings don't tarnish and look like an Astrid & Miyu pair

‘Absolutely resplendent’ Lilac tree that keeps its leaves in the winter lands on sale

An Air Force command halted its use of Sig Sauer's M18 handgun following an airman's death

We lived on a 42-foot sailboat for over a year before moving back on land. The lifestyle wasn't as dreamy as it seemed.

West Point emails reveal how the prestigious military academy messed up Pete Hegseth's admissions status

The US Army fired its new missile system that rattles China in a Western Pacific first. It found its target and sank it.

ChatGPT was a homework cheating tool. Now OpenAI is carving out a more official role in education.

A new spin-off from Tom Purcell's Alua Capital joins the Tiger Cub family tree

Trump Tariffs Cool Small Business Dealmaking, Particularly In Manufacturing

Will Viktor Gyokeres Really Turn Arsenal Into Title Winners?

Netflix Renews Jenna Ortega’s Hit Series ‘Wednesday’ For Third Season

Emmanuel Macron And Wife Brigitte Sue Right-Wing Influencer Candace Owens

FC Barcelona Officially Announces New First Team Transfer

Rich Hill Ties MLB Record Pitching For 14th Team At Age 45

Skydance Plans CBS News Revamp: Ombudsman, ‘Diversity Of Viewpoints—And No DEI

U.S. Home Sales Slid 2.7% In June As Prices Reach All-Time High

Nascar’s San Diego Announcement Is The Next Step In A Nationwide Takeover

Why Your Company’s Future Depends On Thinking Like A Disruptor Today

Barcelona Can Unlock Marcus Rashford, But He Must Do So First

GENIUS Act Passage Calls For Rethink Of Sam Bankman-Fried’s Conviction

Rays Pitcher Hunter Bigge Recovering Nicely One Month After Being Struck By Foul Ball

New York City FC And Partners Turn Concrete Into Community With ‘26 For 26’

Meghan And Harry Lose Their Netflix Deal, Reports Say—Here's What Happens To Meghan's Show

Horror Thriller ’28 Years Later’ Gets Streaming Date, Report Says

What Venus Williams’ DC Open Win Says About Women’s Tennis

Ethan Holliday Following Dad Matt, Brother Jackson On Path To Majors

B.C. premier, Washington state senator to speak live on impact of Trump tariffs

Nova Scotia must double housing starts to restore pre-COVID affordability: report

Alberta pays out $143 million to mining company over coal policy reversal

Rogers looks for cost savings in sports portfolio after becoming MLSE majority owner

FTSE 100 hits new high amid US trade talk optimism

FTSE 100 hits new high amid US trade talk optimism

EU and Japan agree to work together to promote free trade and economic security

US home sales slip in June with mortgages rates high and prices hitting unprecedented levels

US home sales fade in June as prices soar to record levels

Japanese leader Ishiba vows to remain despite speculation, says he will focus on new US trade deal

Instagram blocks 135K accounts for preying on kids, adds safety features

Spring homebuying season a bust as sales drop to 9-month low — and prices hit all-time high

Krispy Kreme, GoPro and Beyond Meat shares soar in revival of meme stock craze

Microsoft says China-backed cybercriminals hacked into US nuclear weapons agency

Uber is finally releasing the feature I've been waiting for — a female driver option

TPG revives Debenhams links with £175m Boohoo debt deal